Jim Glazen

Tiny Accentia Biopharmaceuticals May Be On Its Way To Big Things

Sinunase may or may not get approved. I doubt it personally. However, in my opinion, Biovax is worth zero. Favrille and Genitope have similar vaccines and Rituxan is already the class leader. I don't see Biovax first to market and I certainly don't see any value in an also ran. Revimmune is a pipe dream in my opinion.

What the funding crisis? I heard Biovest can't even make payroll. This company needs big cash and fast.

Tiny Accentia Biopharmaceuticals May Be On Its Way To Big Things

Accentia just hit a new all-time low today. Sounds like Fred is trying to get someone to bail him out of his long position. I think bankruptcy is probably coming soon. Low on cash, no partnerships, high cash burn and lots of promotional press releases.

I have a very bad feeling about this one.